Trials / Terminated
TerminatedNCT04240886
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Basilea Pharmaceutica · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fosmanogepix | IV and oral fosmanogepix |
Timeline
- Start date
- 2020-01-04
- Primary completion
- 2022-03-29
- Completion
- 2022-05-09
- First posted
- 2020-01-27
- Last updated
- 2025-09-16
- Results posted
- 2023-05-19
Locations
15 sites across 4 countries: United States, Belgium, Germany, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04240886. Inclusion in this directory is not an endorsement.